Entheon Biomedical Inc.

Private Company

Company Logo
upcoming listing

Company Overview

Entheon Biomedical Corp. is a psychedelic-drug development company focused on treating substance-use disorder. In particular, the company is committed to the legal development of safe and effective psychedelic medicines, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.

Aware of the growing crisis of substance-use disorder and overdose all over the world, Entheon is developing a DMT therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. The company's chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder who are wanting to reclaim their lives.

Management Team

Timothy Ko
Chief Executive Officer

Brandon Schwabe
Chief Financial Officer

Andrew Hegle, Ph.D.
Chief Science Officer
Director of Operations

Christopher Gondi, Ph.D., M.Sc.
Chief Scientific Officer

Yaron Eshel
Project Manager

Scientific Advisors

Professor Matthew W. Johnson, Ph.D., M.A.
Scientific Advisor

Robin Carhart-Harris, Ph.D.
Scientific Advisor

Dennis McKenna, Ph.D.
Scientific Advisor

Christopher Timmermann, Ph.D.
Scientific Advisor

Malin Vedoy Uthaug, Ph.D.
Scientific Advisor

Dr. Michael Walker
Scientific Advisor

Christopher Gondi, Ph.D., M.Sc.

Kenneth Tupper, Ph.D.
Advisor of Ethics

Sign Up for Alerts

Receive an email alert every time a company announces a merger, capital raise or files for an IPO.

Company Profile